The core function of the Screening Group (SCR) at IARC is to provide data on the accuracy, reproducibility, efficacy, benefits, harmful effects, and cost-effectiveness of various early detection interventions for breast, cervical, colorectal, and oral cancers, among others, in reducing deaths and improving patients’ quality of life in various settings. These data can then be used to inform and improve the rational use of health-care resources. The Group’s ultimate objective is to guide the development of public health policies for implementing screening in a variety of health-care settings, in particular in low- and middle-income countries (LMICs).
SCR conducts field studies in LMICs to evaluate various early detection methods for breast, cervical, colorectal, and oral cancer control. These initiatives also address the means by which screening services could be scaled up through local public health services. SCR develops various training resources to catalyse and augment capacity building in close collaboration with national institutions and government health services. Through its research programme, SCR generates scientific evidence to support the development of resource-appropriate early detection policies and health systems for the delivery of effective early services. The Cancer Screening in 5 Continents (CanScreen5) project of the Group aims to collect information on characteristics and performance of cancer screening programmes around the world and disseminate such information for informed decision making in cancer screening programmes. For example, the Group significantly contributed also to the evaluation of the safety and efficacy of less than three doses of the HPV vaccine in protecting against cervical cancer.
New publication: Strengthening the early detection of common cancers in the Eastern Mediterranean Region06/12/2019
Cancer is the fourth leading cause of death in the Eastern Mediterranean Region with an estimated 676 500 new cases and 419 000 cancer deaths in 2018. The most common cancers in the region are respectively breast, colorectal, lung, liver and bladder. Authors of this editorial concluded that breast, colorectal and cervical cancer can be more effectively managed and prioritized through adoption of the suitable national early detection strategy when feasible.
Read the article
New publication: New study provides baseline to measure impact of cervical cancer elimination objectives05/12/2019
Meeting: iPAAC, Innovative Partnership For Action Against Cancer, Helsinki, Finland04/12/2019 – 05/12/2019
Dr. Partha Basu attended this technical meeting within the framework of the iPAAC project organized by the Cancer Society of Finland to discuss the roadmap and deliverables to take a look into new developments and screening criteria and the new openings of cancer screening in Europe.
Given Tuesday 201903/12/2019
Get ready for the Giving Tuesday 2019 and support research on cancer prevention. Donate to increase the impact of International Agency for Research on Cancer global projects! Find out more about CanScreen5 project which improves the quality of cancer screening practices worldwide.
Read more about how to support IARC and learn more about opportunities of giving Tuesday 2019
Visit of Dr Zhihua Liu02/12/2019 – 20/12/2019
Dr Zhihua Liu from the Shenzhen Maternity and Child Healthcare Hospital, Shenzhen, China visited the Screening group to discuss areas of potential collaboration.
|Pourghazian N., Sankaranarayanan R., Alhomoud S., Slama S. Strengthening the early detection of common cancers in the Eastern Mediterranean Region. East Mediterr Health J. 2019 Nov 25;25(11):767-768. doi: 10.26719/2019.25.11.767.|
|Pinder L.F., Parham G.P., Basu P., Muwonge R., Lucas E., Nyambe N., Sauvaget C., Mwanahamuntu M.H., Sankaranarayanan R., Prendiville W. Thermal ablation versus cryotherapy or loop excision to treat women positive for cervical precancer on visual inspection with acetic acid test: pilot phase of a randomised controlled trial. Lancet Oncol. 2019 Nov 13. pii: S1470-2045(19)30635-7.|
|Sankaranarayanan R., Basu P., Kaur P., Bhaskar R., Singh G.B., Denzongpa P., Grover R.K., Sebastian P., Saikia T., Oswal K., Kanodia R., Dsouza A., Mehrotra R., Rath G.K., Jaggi V., Kashya S., Kataria I., Hariprasad R., Sasieni P., Bhatla N., Rajaraman P., Trimble E.L., Swaminathan S., Purushotham A. Current status of human papillomavirus vaccination in India's cervical cancer prevention efforts. Lancet Oncol. 2019 Nov;20(11):e637-e644.|